Abstract
Bronchiolitis obliterans syndrome (BOS) is a devastating pulmonary complication affecting long-term survivors of allogeneic hematopoietic cell transplantation. Treatment of BOS with prolonged courses of high dose corticosteroids is often associated with significant morbidity. Reducing the exposure to corticosteroids may reduce treatment-related morbidity. Our institution has recently begun to treat patients with emerging therapies in an effort to diminish corticosteroid exposure. We retrospectively reviewed the 6-month corticosteroid exposure, lung function and failure rates in eight patients with newly diagnosed BOS who were treated with a combination of fluticasone, azithromycin and montelukast (FAM) and a rapid corticosteroid taper. These patients were compared with 14 matched historical patients who received high-dose corticosteroids, followed by a standard taper. The median 6-month prednisone exposure in FAM-treated patients was 1819 mg (0–4036 mg) compared with 7163 mg (6551–7829 mg) in the control group (P=0.002). The median forced expiratory volume in 1 s (FEV1) change in FAM-treated patients was 2% (−3 to 4%] compared with 1% (−4 to 5%) in the control group (P=1.0). Prednisone exposure in FAM patients was one quarter that of a retrospective-matched group of patients, with minimal change in median FEV1, suggesting that BOS may be spared of the morbidities associated with long-term corticosteroid use by using alternative agents with less side effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW . Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood 1988; 72: 621–627.
Clark JG, Crawford SW, Madtes DK, Sullivan KM . Obstructive lung disease after allogeneic bone marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111: 368–376.
Dudek AZ, Mahaseth H, Defor TE, Weisdorf DJ . Bronciolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657–666.
Santo Tomas LH, Loberiza Jr FR, Klein JP, Layde PM, Lipchik RJ, Rizzo JD et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153–161.
Chan CK, Hyland RH, Hutcheon MA, Minden MD, Alexander MA, Kossakowaska AE et al. Small-airways disease in recipients of allogeneic bone marrow transplants.An analysis of 11 cases and a review of the literature. Medicine (Baltimore) 1987; 66: 327–340.
Philit F, Wiesendanger T, Archimbaud E, Mornex JF, Brune J, Cordier JF . Post-transplant obstructive lung disease (‘bronchiolitis obliterans’): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995; 8: 551–558.
Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ . Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657–666.
Van Staa TP, Leufkens HGM, Cooper C . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777–787.
Fardet L, Kassar A, Cabane J, Flahault A . Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007; 30: 861–881.
Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ . Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1100–1107.
Clore JN, Thurby-Hay L . Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15: 469–474.
McDonough AK, Curtis JR, Saag KG . The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008; 20: 131–137.
Griffith LM, Pavletic SZ, Lee SJ, Martin PJ, Schultz KR, Vogelsang GB . Chronic graft-versus-host disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant 2008; 14: 379–384.
Lee SJ, Flowers ME . Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008, 134–141.
Crapo RO, Morris AH, Gardner RM . Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659–664.
Hsu KH, Jenkins DE, Hsi BP, Bourhofer E, Thompson V, Tanawaka N et al. Ventilatory functions of normal children and young adults--Mexican-American, white, and black. I Spirometry J Pediatr 1979; 95: 14–23.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckber SR, Nichols WG et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208–214.
Bergeron A, Belle A, Chevret S, Ribdbaud P, Devergie A, Esperou H et al. Combined inhaled steroids and bronchodilators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 547–553.
Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 63–67.
Khalid M, Saghir Al, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005; 25: 490–493.
Medoff BD, Seung E, Wain JC, Means TK, Campanella GS, Islam SA et al. BLT-1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med 2005; 202: 97–110.
Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M . Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996; 97: 1827–1836.
Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007; 83: 577–581.
Acknowledgements
Financial disclosure: This work was supported in part by the National Institutes of Health Grants HL088201 and AI083028.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Norman, B., Jacobsohn, D., Williams, K. et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 46, 1369–1373 (2011). https://doi.org/10.1038/bmt.2010.311
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.311
Keywords
This article is cited by
-
Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Stem Cell Research & Therapy (2023)
-
Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally
Bone Marrow Transplantation (2019)
-
Decline of forced expiratory volume in 1 s after allogeneic hematopoietic cell transplantation is a good indicator for pulmonary damage and is associated with busulfan use
International Journal of Hematology (2019)
-
Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease
Lung (2017)
-
Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
Respiratory Research (2016)